Skip to main content

Table 2 Targeted nucleases to oncogenic viruses

From: Designer nucleases to treat malignant cancers driven by viral oncogenes

Viral target Modality Target Cell lines In vivo Vector Delivery method Reference
HPV spCas9 or dspCas9-FokI E6, E7, LCR SiHa Yes Plasmid DNA No [27, 111]
E6, E7 Hela, SiHa No Plasmid DNA No [28]
E7 SiHa, CaSki No Plasmid DNA No [30]
E6 Hela, HSC-2, SKG-I Yes AAV genome AAV-2a
(intratumoral)
[32]
E6, E7 Hela, CaSki Yes Plasmid DNA ‘Stealth’ Liposomes
(Intravenous)
[37]
E6, E7 Hela No Plasmid DNA No [47]
E6, E7 SCC2 No Plasmid DNA No [33]
TALEN E6, E7 SiHa, S12, Hela Yes Plasmid DNA Cationic polymer
(Topical)
[35]
E7 SiHa, CaSki No Plasmid DNA No [48, 49]
ZFN E7 SiHa, Hela, CaSki, S12 Yes Plasmid DNA Cationic polymer (Intratumoral) [36]
BEF LCR Hela No Plasmid DNA No [38]
AZP-SNase or scFokI LCR None No Plasmid DNA, Protein No [39,40,41, − 42, 46]
HTLV-1 ZFN LTR C8166, S1T, ED Yes Plasmid DNA No [67]
EBV (HHV-4) spCas9 EBNA-LP, 125 bp repeat, EBNA3C, EBNA1, pstI repeat, LMP1 Raji No Plasmid DNA No [78]
EBNA1, oriP, miRNA promoter SNU-719 No Lentiviral vector No [79]
LMP1 EBV infected cell line No Plasmid DNA No [87]
EBNA1, oriP and W repeats C666-1 No Plasmid DNA No [80]
  TALEN EBNA1 Raji, SNU-719, SNU-265 No Plasmid DNA No [77]
KSHV
(HHV-8)
spCas9 LANA Vero219, L1T2, BC3 No Adenoviral genome Replication-deficient Ad5
(Intratumoral)
[84]
K12-miR promoter miR-K12-1
miR-K12-9
BCP-1, BCBL-1 No Plasmid DNA No [90]
MCPyV spCas9 LT and sT MS-1, WaGa No Plasmid DNA No [106]
  1. The modalities that have been developed against their respective oncogenic viruses and targets in each study are shown. The in vitro cell lines as well as whether in vivo studies were performed are highlighted. The delivery vectors developed are indicated along with the route of administration used in vivo. The expression vector used for the different nuclease modalities are indicated
  2. aAAV delivered gRNA to Cas9 overexpressing cell line